NASDAQ:RNAZ TransCode Therapeutics (RNAZ) Stock Price, News & Analysis → Charles Payne’s Gift to Stock Investors (From Unstoppable Prosperity) (Ad) Free RNAZ Stock Alerts $0.60 +0.05 (+9.15%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$0.53▼$0.6350-Day Range$0.44▼$0.7352-Week Range$0.42▼$309.60Volume1.17 million shsAverage Volume611,488 shsMarket Capitalization$3.47 millionP/E RatioN/ADividend YieldN/APrice Target$480.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get TransCode Therapeutics alerts: Email Address TransCode Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside80,382.9% Upside$480.00 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.14) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.05 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTransCode Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTransCode Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the float of TransCode Therapeutics has been sold short.Short Interest Ratio / Days to CoverTransCode Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TransCode Therapeutics has recently decreased by 53.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTransCode Therapeutics does not currently pay a dividend.Dividend GrowthTransCode Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNAZ. Previous Next 2.8 News and Social Media Coverage News SentimentTransCode Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TransCode Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.47% of the stock of TransCode Therapeutics is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TransCode Therapeutics are expected to grow in the coming year, from ($2.14) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransCode Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TransCode Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTransCode Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About TransCode Therapeutics Stock (NASDAQ:RNAZ)TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Read More RNAZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNAZ Stock News HeadlinesApril 17, 2024 | uk.investing.comFDA clears TransCode's drug trial for advanced tumorsApril 15, 2024 | globenewswire.comTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsApril 29, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.April 4, 2024 | markets.businessinsider.comPromising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode TherapeuticsApril 3, 2024 | globenewswire.comTransCode Therapeutics Reports 2023 Results; Provides Business UpdateMarch 30, 2024 | uk.investing.comTransCode Therapeutics appoints new Chief Medical OfficerMarch 29, 2024 | markets.businessinsider.comTransCode Appoints Daniel Vlock As CMOMarch 28, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerApril 29, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.March 28, 2024 | globenewswire.comTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 11, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 11, 2024 | globenewswire.comTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 6, 2024 | globenewswire.comTransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressFebruary 20, 2024 | finance.yahoo.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticFebruary 20, 2024 | globenewswire.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist ImmunotherapeuticFebruary 1, 2024 | uk.investing.comTranscode Therapeutics Inc (RNAZ)January 31, 2024 | finance.yahoo.comNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketJanuary 30, 2024 | benzinga.comLooking Into TransCode Therapeutics's Recent Short InterestJanuary 29, 2024 | markets.businessinsider.comTransCode Collaborates With Debiopharm; Financial Terms Not DisclosedJanuary 29, 2024 | finance.yahoo.comTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerJanuary 22, 2024 | finance.yahoo.comTransCode Therapeutics Announces Closing of $7.25 Million Public OfferingJanuary 19, 2024 | msn.comWhy TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 18, 2024 | marketwatch.comTransCode Therapeutics Shares Slide to 52-Week Low on Planned Public OfferingJanuary 18, 2024 | finance.yahoo.comTransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingJanuary 15, 2024 | finanznachrichten.deTransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitJanuary 14, 2024 | benzinga.comTransCode Therapeutics Stock (NASDAQ:RNAZ) Dividends: History, Yield and DatesJanuary 12, 2024 | marketwatch.comStocks to Watch: TransCode Therapeutics, Rackspace Technology, Williams-SonomaSee More Headlines Receive RNAZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today4/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNAZ CUSIPN/A CIK1829635 Webwww.transcodetherapeutics.com Phone857-837-3099FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$480.00 High Stock Price Target$480.00 Low Stock Price Target$480.00 Potential Upside/Downside+80,382.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($774.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,550,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-934.78% Return on Assets-276.08% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.62 per share Price / Book0.23Miscellaneous Outstanding Shares5,810,000Free Float5,723,000Market Cap$3.47 million OptionableNot Optionable Beta-0.35 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Thomas A. Fitzgerald M.B.A. (Age 72)Interim CEO, CFO, President, VP of Administration & Director Comp: $358.14kDr. Philippe P. Calais Ph.D. (Age 65)Pharm., Pharm.D., Executive Chairman of the Board Comp: $102.5kDr. Zdravka Medarova Ph.D. (Age 49)Co-Founder & Chief Scientific Officer Dr. Anna Moore Ph.D. (Age 62)Co-Founder, Scientific Advisor & Member of Scientific Advisory Board Ms. Susan Duggan M.B.A.R.N., Senior Vice President of OperationsDr. Daniel R. Vlock M.D. (Age 72)Chief Medical Officer More ExecutivesKey CompetitorsOnconetixNASDAQ:ONCOAgile TherapeuticsNASDAQ:AGRXCohBarNASDAQ:CWBRNovaBay PharmaceuticalsNYSE:NBYAltamira TherapeuticsNASDAQ:CYTOView All CompetitorsInsidersRobert Michael DudleyBought 2,450 shares on 9/28/2023Total: $49,980.00 ($20.40/share)Thomas A FitzgeraldBought 1,233 shares on 9/28/2023Total: $25,153.20 ($20.40/share)Robert Michael DudleyBought 165 shares on 6/20/2023Total: $16,830.00 ($102.00/share)Robert Michael DudleyBought 475 shares on 6/9/2023Total: $52,440.00 ($110.40/share)View All Insider Transactions RNAZ Stock Analysis - Frequently Asked Questions Should I buy or sell TransCode Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransCode Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNAZ shares. View RNAZ analyst ratings or view top-rated stocks. What is TransCode Therapeutics' stock price target for 2024? 1 brokerages have issued 1-year target prices for TransCode Therapeutics' stock. Their RNAZ share price targets range from $480.00 to $480.00. On average, they predict the company's share price to reach $480.00 in the next year. This suggests a possible upside of 80,382.9% from the stock's current price. View analysts price targets for RNAZ or view top-rated stocks among Wall Street analysts. How have RNAZ shares performed in 2024? TransCode Therapeutics' stock was trading at $6.5920 at the beginning of the year. Since then, RNAZ stock has decreased by 91.0% and is now trading at $0.5964. View the best growth stocks for 2024 here. Are investors shorting TransCode Therapeutics? TransCode Therapeutics saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 18,600 shares, a decrease of 53.5% from the March 31st total of 40,000 shares. Based on an average daily volume of 588,800 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.3% of the shares of the company are sold short. View TransCode Therapeutics' Short Interest. When is TransCode Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RNAZ earnings forecast. How were TransCode Therapeutics' earnings last quarter? TransCode Therapeutics, Inc. (NASDAQ:RNAZ) released its quarterly earnings data on Tuesday, November, 14th. The company reported ($67.20) earnings per share for the quarter, missing the consensus estimate of ($60.00) by $7.20. When did TransCode Therapeutics' stock split? Shares of TransCode Therapeutics reverse split on the morning of Tuesday, January 16th 2024. The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did TransCode Therapeutics IPO? TransCode Therapeutics (RNAZ) raised $25 million in an IPO on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share. How do I buy shares of TransCode Therapeutics? Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNAZ) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
